JP2002223726A - Food for beauty - Google Patents
Food for beautyInfo
- Publication number
- JP2002223726A JP2002223726A JP2001024457A JP2001024457A JP2002223726A JP 2002223726 A JP2002223726 A JP 2002223726A JP 2001024457 A JP2001024457 A JP 2001024457A JP 2001024457 A JP2001024457 A JP 2001024457A JP 2002223726 A JP2002223726 A JP 2002223726A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- skin
- food
- test
- glucosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 48
- 230000003796 beauty Effects 0.000 title claims abstract description 26
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 86
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 85
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 85
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 39
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 38
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 30
- 229960002442 glucosamine Drugs 0.000 claims abstract description 30
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 24
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 24
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 19
- 239000011718 vitamin C Substances 0.000 claims abstract description 19
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 19
- 239000002537 cosmetic Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 12
- FZHXIRIBWMQPQF-SLPGGIOYSA-N aldehydo-D-glucosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FZHXIRIBWMQPQF-SLPGGIOYSA-N 0.000 claims description 9
- 241000561734 Celosia cristata Species 0.000 claims description 7
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 claims description 7
- 210000001520 comb Anatomy 0.000 claims description 7
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 5
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 claims description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 5
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 5
- 229920002101 Chitin Polymers 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 241000264435 Streptococcus dysgalactiae subsp. equisimilis Species 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 230000037406 food intake Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 53
- 238000012360 testing method Methods 0.000 description 39
- 230000000694 effects Effects 0.000 description 25
- 235000005911 diet Nutrition 0.000 description 20
- 230000037213 diet Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- 230000000968 intestinal effect Effects 0.000 description 15
- 230000006872 improvement Effects 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 241000186000 Bifidobacterium Species 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 241000186660 Lactobacillus Species 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010013786 Dry skin Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- -1 sucrose ester Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 150000008273 hexosamines Chemical class 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229940049496 hyaluronic acid 30 mg Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は美容食品に関するも
のであり、より具体的にはヒアルロン酸を含むことを特
徴とする美容食品に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a beauty food, and more particularly to a beauty food containing hyaluronic acid.
【0002】[0002]
【従来の技術】肌荒れの防止、及び小皺の改善は人間だ
れしも願望するところであり、色々の肌用の化粧品等が
今までに開発されてきた。BACKGROUND OF THE INVENTION Prevention of rough skin and improvement of fine wrinkles are desired by all human beings, and various cosmetics for skin and the like have been developed.
【0003】これらの化粧品は基本的に皮膚の構成、組
成等を考慮して形成されており、皮膚の構成、組成等を
具体的に説明すると、皮膚は表皮、真皮、皮下細胞組織
からなり、表皮には表皮細胞の外にメラノサイト、ラン
ゲルス細胞等が存在し、表皮の最表面部には角質層でケ
ラチンとよばれる非常に強固で安定した細胞骨格蛋白と
角質細胞間脂質とを備え、ケラチンは、天然保湿因子と
よばれるピリドンカルボン酸ソーダ等のアミノ酸を含み
皮膚の保湿機能に重要な役割を果たしている。このた
め、これらの天然保湿因子様の物質が保湿資材として美
容化粧品に利用されてきた。[0003] These cosmetics are basically formed in consideration of the composition and composition of the skin. When the composition and composition of the skin are specifically described, the skin is composed of epidermis, dermis, and subcutaneous cell tissues. In the epidermis, there are melanocytes, Langer's cells, etc. in addition to the epidermal cells, and the outermost surface of the epidermis has a very strong and stable cytoskeletal protein called keratin in the stratum corneum and keratin intercellular lipids. Contains an amino acid such as sodium pyridonecarboxylate, which is called a natural moisturizing factor, and plays an important role in the moisturizing function of the skin. For this reason, these natural moisturizing factor-like substances have been used in cosmetics and cosmetics as moisturizing materials.
【0004】又、皮膚の真皮は線維、基質、細胞成分か
らなり、線維成分は膠原線維、弾力線維、細網線維等か
らなり、真皮の基質は線維成分の間を充填する無定形の
成分であり、細胞成分は線維成分や基質を産生する線維
芽細胞等よりなり、この中でも膠原線維のコラーゲンは
真皮の乾燥重量の75%を占め重要な成分であり、皮膚
の弾力性に関係すると共に、加齢とともに減少して皮膚
の弾力性を失わせ、皮膚のタルミや皺の原因になってい
る。このため、コラーゲンを補給するよう化粧品の中に
含有させる美肌用化粧品が開発されてきた。なお、コラ
ーゲンは健康食品としても経口摂取されるようになって
きたが、美容食品としての効果は確認されていない。[0004] The dermis of the skin is composed of fibrous, matrix and cellular components. The fibrous component is composed of collagen fibers, elastic fibers, reticulum fibers and the like, and the dermal matrix is an amorphous component filling the space between the fibrous components. There, the cell component consists of fibroblasts that produce fibrous components and matrix, among which collagen collagen collagen is an important component occupying 75% of the dry weight of the dermis, and is related to the elasticity of the skin, It decreases with age and causes the skin to lose its elasticity, causing skin lumps and wrinkles. For this reason, cosmetics for beautiful skin which are contained in cosmetics to replenish collagen have been developed. Collagen has also come to be taken orally as a health food, but its effect as a beauty food has not been confirmed.
【0005】更に、皮膚の基質中には機能上重要な物質
としてヒアルロン酸、デルマタン硫酸等のムコ多糖があ
り、ヒアルロン酸は、他のムコ多糖に比較して保水力に
富むことから皮膚の柔軟性、弾力性を維持する役目を
し、しかもコラーゲンと同様に加齢とともに減少するた
め、美肌に重要な要因であるヒアルロン酸を補給するよ
う化粧品の中に含有させる美肌用化粧品が開発されてい
る。その中でも特開平5-111367号公報、特開2
000-102362号公報に示す如く、ヒアルロン酸
を組成物とする食品を経口摂取するものがあり、上記公
報に示す食品は、腸管吸収を容易にし得るよう、高分子
量のヒアルロン酸を高温、高圧処理、或いは酵素処理で
低分子化し、経口摂取した際には、種々の活性化作用に
より美肌効果を出すものである。Further, there are mucopolysaccharides such as hyaluronic acid and dermatan sulfate as functionally important substances in the skin matrix, and hyaluronic acid is rich in water retention compared to other mucopolysaccharides. It has a role to maintain the elasticity and elasticity, and it decreases with age like collagen, so cosmetics for beautiful skin have been developed to contain hyaluronic acid, which is an important factor for beautiful skin, in cosmetics. . Among them, Japanese Patent Application Laid-Open Nos.
As described in Japanese Patent Application Laid-Open No. 000-102362, some foods containing hyaluronic acid as a composition are orally ingested. In the foods described in the above-mentioned Japanese Patent Application, high-molecular-weight hyaluronic acid is subjected to high-temperature and high-pressure treatment so as to facilitate intestinal absorption. Or, when it is reduced in molecular weight by enzymatic treatment and taken orally, it exerts a beautiful skin effect by various activating effects.
【0006】[0006]
【発明が解決しようとする課題】しかしながら、上記引
用文献には、ヒアルロン酸が動物の体内で利用されると
いう確証あるデーターは殆どなく、しかも、美肌作用を
一層高めることが求められていた。However, in the above cited document, there is almost no confirmed data that hyaluronic acid is used in the body of an animal, and furthermore, it is required to further enhance the action of beautiful skin.
【0007】本発明は、ヒアルロン酸の美肌作用を著し
く向上させることを目的としてなされた美容食品であ
る。[0007] The present invention is a cosmetic food made for the purpose of significantly improving the beautiful skin effect of hyaluronic acid.
【0008】[0008]
【課題を解決するための手段】本発明の請求項1の美容
食品は、ヒアルロン酸、グルコサミン、オリゴ糖及びビ
タミンCを含むものである。The cosmetic food of claim 1 of the present invention contains hyaluronic acid, glucosamine, oligosaccharide and vitamin C.
【0009】本発明の請求項2の美容食品は、全体の1
の重量に対して、ヒアルロン酸の重量比を0.01〜
0.25、グルコサミンの重量比を0.005〜0.1
5、オリゴ糖の重量比を0.02〜0.35、ビタミン
Cの重量比を0.01〜0.25にしたものである。[0009] The beauty food according to claim 2 of the present invention is characterized in that
Weight ratio of hyaluronic acid to 0.01 to
0.25, the weight ratio of glucosamine is 0.005 to 0.1
5. The weight ratio of oligosaccharide is 0.02 to 0.35, and the weight ratio of vitamin C is 0.01 to 0.25.
【0010】本発明の請求項3の美容食品は、ヒアルロ
ン酸の分子量を60万から200万にしたものである。[0010] The cosmetic food according to claim 3 of the present invention has a molecular weight of hyaluronic acid of 600,000 to 2,000,000.
【0011】本発明の請求項4の美容食品は、ヒアルロ
ン酸が鶏冠より抽出されたものからなるものである。[0011] The cosmetic food according to claim 4 of the present invention is one in which hyaluronic acid is extracted from a chicken cop.
【0012】本発明の請求項5の美容食品は、ヒアルロ
ン酸が、Streptococcus zoopidemicus、Streptococcus
equisimilisの少なくとも一方の微生物の発酵により製
造されたものからなるものである。[0012] In the beauty food according to the fifth aspect of the present invention, the hyaluronic acid may contain Streptococcus zoopidemicus, Streptococcus.
It is produced by fermentation of at least one microorganism of equisimilis.
【0013】本発明の請求項6の美容食品は、グルコサ
ミンが、キチンを加水分解して製造される2-アミノ-2
-デオキシ-D-グルコース、又は2-アミノ-2-デオキシ-
D-グルコースの塩の少なくとも一方からなるものであ
る。[0013] The beauty food according to claim 6 of the present invention is characterized in that glucosamine is produced by hydrolyzing chitin.
-Deoxy-D-glucose or 2-amino-2-deoxy-
It consists of at least one of the salts of D-glucose.
【0014】本発明の請求項7の美容食品は、オリゴ糖
が、マルトオリゴ糖、ガラクトオリゴ糖、フラクトオリ
ゴ糖、イソマルトオリゴ糖、ゲンチオオリゴ糖、ラクト
スクロース、トレハロースのうち少なくとも1種以上か
らなるものである。[0014] The cosmetic food according to claim 7 of the present invention is characterized in that the oligosaccharide comprises at least one of maltooligosaccharide, galactooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, gentiooligosaccharide, lactosucrose and trehalose.
【0015】本発明の美容食品を経口摂取した際には、
ヒアルロン酸、グルコサミン、オリゴ糖、ビタミンCの
成分の相乗効果により皮膚中のヒアルロン酸やコラーゲ
ンの産生を高める等の優れた美容作用を生じることがで
きる。When the cosmetic food of the present invention is taken orally,
Due to the synergistic effect of the components of hyaluronic acid, glucosamine, oligosaccharides and vitamin C, excellent cosmetic effects such as enhancing production of hyaluronic acid and collagen in the skin can be produced.
【0016】これは、グルコサミン、オリゴ糖、ビタミ
ンCによる次の作用によるものと思われる。This is thought to be due to the following actions of glucosamine, oligosaccharides and vitamin C.
【0017】すなわち、グルコサミンが体内でヒアルロ
ン酸等のプロテオグルカンに変換する可能性が示されて
いるため、グルコサミンを摂取すればヒアルロン酸のよ
うに直接腸内細菌に及ぼす影響は少ないが体内でヒアル
ロン酸に変換され、特に皮膚のヒアルロン酸を増加さ
せ、美容効果を発揮できると思われる。又、ヒアルロン
酸は高分子のために粘度が高く一度に多量に摂取できな
いのでグルコサミンの多量摂取がその効果を補助し、ヒ
アルロン酸と同時に摂取すればヒアルロン酸の作用を増
大させると考えられる。That is, it has been shown that glucosamine can be converted into proteoglycan such as hyaluronic acid in the body. Therefore, ingestion of glucosamine has a small effect on intestinal bacteria directly like hyaluronic acid, but hyaluronic acid in the body. It is considered to be converted into an acid and to increase hyaluronic acid in the skin, in particular, to exert a cosmetic effect. In addition, since hyaluronic acid has a high viscosity due to its high molecular weight and cannot be ingested in large quantities at a time, it is thought that ingestion of a large amount of glucosamine assists its effect, and if it is ingested simultaneously with hyaluronic acid, it is considered that the action of hyaluronic acid is increased.
【0018】ビタミンCは抗酸化作用、活性酸素除去作
用、ウィルスを不活化させる等の効果があり、美肌に関
してはコラーゲンの生成と維持に大きく関与していて皮
膚の細胞の増殖に必須であり、しかも、シミ等の原因で
あるチロシンからメラニンの生成過程を抑制し、更にビ
タミンCは皮膚の老化を遅くし、みずみずしい肌を保つ
ことに効果があることから、ビタミンCはこのような抗
酸化作用によりヒアルロン酸の安定化に効果があり、ヒ
アルロン酸、グルコサミンと同時に摂取すると更に作用
を高めると考えられる。Vitamin C has an antioxidant effect, an active oxygen scavenging effect, an effect of inactivating viruses, and the like. For beautiful skin, it is greatly involved in the production and maintenance of collagen, and is essential for the proliferation of skin cells. In addition, vitamin C has such an antioxidant effect because it suppresses the process of producing melanin from tyrosine, which is the cause of spots, and has the effect of slowing down skin aging and maintaining fresh skin. Is effective in stabilizing hyaluronic acid, and it is considered that the effect is further enhanced when taken simultaneously with hyaluronic acid and glucosamine.
【0019】オリゴ糖は経口摂取されれば分解されず大
腸に到達し、腸内細菌によって利用され腸内フローラー
を構成する菌を有用なラクトバチルス菌やビフィズス菌
が多くなるように変えていくため、乳酸、酢酸等の短鎖
脂肪酸を生成して大腸内pHを酸性にし、これによって便
秘を予防し体内を良好に調節することによって美肌効果
を発揮し、ヒアルロン酸、グルコサミン、ビタミンCに
加えてオリゴ糖を同時に摂取すれば腸内フローラーの改
善を更に増加させヒアルロン酸の作用を一層高める。Oligosaccharides reach the large intestine without being decomposed when taken orally, and are used by intestinal bacteria to change the bacteria constituting the intestinal flora so that useful lactobacilli and bifidobacteria are increased. In addition, it produces short-chain fatty acids such as lactic acid and acetic acid to acidify the pH in the large intestine, thereby preventing constipation and exerting a beautiful skin effect by regulating the body well. In addition to hyaluronic acid, glucosamine and vitamin C, Concomitant use of oligosaccharides further improves intestinal flora and further enhances the action of hyaluronic acid.
【0020】又、ヒアルロン酸、オリゴ糖は消化酵素に
よって消化されず、そのまま大腸に到達し、そこでラク
トバチルス菌、ビフィズス菌等の腸内細菌に利用され、
これらの菌の増殖を促進し、酢酸、乳酸等の脂肪酸を生
成する。これらの脂肪酸は腸内のpHを酸性にして便秘の
防止、大腸癌等の予防になると考えられる。又、これら
の有用なラクトバチルス菌、ビフィズス菌は腐敗菌等の
有害菌の増殖を阻止し、腸内環境を浄化する等の働きも
ある。なお、これらはプレバイオテイクスに該当する。
「結腸内の有用菌の増殖を促進したり、或いは有害菌の
増殖を抑制し、その結果、腸内浄化作用によって宿主の
健康に有利に作用する難消化性食品成分―プレバイオテ
イクス」(光岡知足;腸内フローラと健康 p171,
学会センター)。In addition, hyaluronic acid and oligosaccharides are not digested by digestive enzymes and reach the large intestine as they are, where they are used by intestinal bacteria such as lactobacilli and bifidobacteria,
It promotes the growth of these bacteria and produces fatty acids such as acetic acid and lactic acid. It is considered that these fatty acids acidify the pH in the intestine to prevent constipation and prevent colon cancer and the like. In addition, these useful Lactobacillus and Bifidobacterium also have a function of inhibiting the growth of harmful bacteria such as spoilage bacteria and purifying the intestinal environment. In addition, these correspond to prebiotakes.
“Prebiotics, an indigestible food ingredient that promotes the growth of useful bacteria in the colon or suppresses the growth of harmful bacteria, resulting in a beneficial effect on the health of the host through intestinal purification” (Mitsuoka Shirashi; intestinal flora and health p171,
Society Center).
【0021】このように、皮膚のヒアルロン酸、コラー
ゲンを増加させ、保湿効果や弾力性を増加させたこと
と、腸内フローラーの有用細菌を増加させ、体内から健
康な状態にし、それが肌の改善につながったと思われ
る。今までは皮膚に化粧品を塗布して皮膚の改善を行な
ってきたが、界面活性剤、防腐剤等の影響により敏感性
皮膚の場合等では逆に副作用が現れることがあった。こ
れに対して本発明品の各成分は食品として安全性が確認
された。As described above, the hyaluronic acid and collagen of the skin are increased, the moisturizing effect and elasticity are increased, the useful bacteria of the intestinal flora are increased, and the body is brought into a healthy state. It seems to have led to improvement. Until now, cosmetics have been applied to the skin to improve the skin. However, adverse effects may occur in the case of sensitive skin due to the effects of surfactants, preservatives and the like. In contrast, the safety of each component of the product of the present invention was confirmed as food.
【0022】更に、本発明の美容食品は、ヒアルロン酸
の分子量を60万から200万にすると、50万以下の
低分子量のものに比べて腸内のラクトバチルス菌、ビフ
ィズス菌を増加させるので整腸作用を増進し、美容作用
を一層高めることができる。Further, when the molecular weight of hyaluronic acid is from 600,000 to 2,000,000, the beauty food of the present invention increases the number of lactobacilli and bifidobacteria in the intestine as compared with those having a low molecular weight of 500,000 or less. Bowel action can be enhanced and cosmetic action can be further enhanced.
【0023】ヒアルロン酸を鶏冠より抽出し若しくは微
生物の発酵により製造させると、従来、ヒアルロン酸を
50万以下の分子量にするために必要であった高圧、高
温、酵素の処理を不要にし、製造コストを低減すること
ができる。When hyaluronic acid is extracted from a cockscomb or produced by fermentation of microorganisms, high-pressure, high-temperature, and enzyme treatments conventionally required to reduce the molecular weight of hyaluronic acid to 500,000 or less are unnecessary, and the production cost is reduced. Can be reduced.
【0024】グルコサミンを、2-アミノ-2-デオキシ-
D-グルコース又は2-アミノ-2-デオキシ-D-グルコース
の塩で構成し、オリゴ糖を、マルトオリゴ糖、ガラクト
オリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖、ゲ
ンチオオリゴ糖、ラクトスクロース、トレハロースのう
ち少なくとも1種以上で構成すると、美容作用を高める
と共に製造コストを一層低減することができる。Glucosamine is converted to 2-amino-2-deoxy-
D-glucose or 2-amino-2-deoxy-D-glucose salt, wherein the oligosaccharide is at least one of maltooligosaccharide, galactooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, gentiooligosaccharide, lactosucrose and trehalose With the above configuration, the cosmetic effect can be enhanced and the manufacturing cost can be further reduced.
【0025】[0025]
【発明の実施の形態】以下、本発明の美容食品を実施す
る形態例を説明する。BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, an embodiment of a beauty food of the present invention will be described.
【0026】本発明の美容食品を製造する場合には、始
めにヒアルロン酸、グルコサミン、オリゴ糖、ビタミン
C(アスコルビン酸)、賦形剤等を準備する。When producing the cosmetic food of the present invention, first, hyaluronic acid, glucosamine, oligosaccharide, vitamin C (ascorbic acid), excipients and the like are prepared.
【0027】ここで、準備されるヒアルロン酸は、鶏冠
を生の状態で細断してリパーゼとプロテアーゼ等の酵素
により処理し、鶏冠に含有される脂肪を分解することに
よって、分子量60万から200万で高純度に製造され
ており、Streptococcus zoopidemicus、Streptococcus
equisimilis等の微生物の発酵により製造させてもよ
い。なお、ヒアルロン酸は当然に安全性が高く、食品添
加物の規格に合格したものである。Here, the prepared hyaluronic acid is obtained by chopping the cockscomb in a raw state, treating it with enzymes such as lipase and protease, and decomposing fat contained in the cockscomb to obtain a molecular weight of 600,000 to 200,000. Manufactured in high purity at 10,000, Streptococcus zoopidemicus, Streptococcus
It may be produced by fermentation of a microorganism such as equisimilis. It should be noted that hyaluronic acid naturally has high safety and has passed the standards for food additives.
【0028】又、準備されるグルコサミンは、主として
甲殻類の殻に含有されるキチンを濃硫酸で加水分解して
単糖のN-アセチルグルコサミンを生成し、N-アセチルグ
ルコサミンのアセチル基を除去することにより2-アミ
ノ-2-デオキシ-D-グルコース等のヘキソサミン、もし
くは2-アミノ-2-デオキシ-D-グルコースの塩酸塩、硫
酸塩等のヘキソサミン塩として製造されており、実施の
形態例ではグルコサミンを結晶化させるために塩酸塩、
或いは硫酸塩の形で製造されたものを用いている。な
お、グルコサミンは、動物体内の軟骨や結合組織に広く
分布しているプロテオグルカン等の構成成分であり、経
口摂取して急性及び慢性関節炎の治療として使用されて
いる例もあり、安全性が高いものである。The prepared glucosamine mainly hydrolyzes chitin contained in shells of crustaceans with concentrated sulfuric acid to produce monosaccharide N-acetylglucosamine and removes the acetyl group of N-acetylglucosamine. Thus, it is produced as a hexosamine such as 2-amino-2-deoxy-D-glucose or a hexosamine salt such as a hydrochloride or a sulfate of 2-amino-2-deoxy-D-glucose. Hydrochloride to crystallize glucosamine,
Alternatively, those manufactured in the form of sulfate are used. In addition, glucosamine is a component such as proteoglucan widely distributed in cartilage and connective tissue in the animal body, and there are cases where it is ingested orally and used as a treatment for acute and chronic arthritis, which is highly safe. Things.
【0029】更に、準備されるオリゴ糖は、特に限定さ
れないがマルトオリゴ糖、ガラクトオリゴ糖、フラクト
オリゴ糖、イソマルトオリゴ糖、ゲンチオオリゴ糖、ラ
クトスクロース、トレハロース等から選択されるものを
用い、ビタミンCは、一般に製造流通しているものを用
いている。The oligosaccharide to be prepared is not particularly limited, but may be selected from maltooligosaccharides, galactooligosaccharides, fructooligosaccharides, isomaltooligosaccharides, gentiooligosaccharides, lactosucrose, trehalose and the like. We use those that are manufactured and distributed.
【0030】更に又、賦形剤は、デキストリン、コーン
スターチ、乳糖、還元麦芽等水飴、ショ糖エステル、パ
ラチノース、ゼラチン、セルロース等、エリスリトー
ル、グルコース、キシリトール、マンニトール等から選
択されるものを用い、又、適宜、クエン酸、酒石酸等の
pH調節剤、種々の香料、ソルビン酸等の保存料、乳化剤
等を使用する。Further, as the excipient, those selected from dextrin, corn starch, lactose, starch syrup such as reduced malt, sucrose ester, palatinose, gelatin, cellulose, etc., erythritol, glucose, xylitol, mannitol and the like are used. , As appropriate, citric acid, tartaric acid, etc.
pH adjusters, various flavors, preservatives such as sorbic acid, emulsifiers and the like are used.
【0031】ヒアルロン酸、グルコサミン、オリゴ糖、
ビタミンC、賦形剤等を準備した後には所定量に秤量し
て攪拌器により混合し、混合物を打錠器により打錠して
所定の形状にし、衣を付けるよう下掛け及び中掛けを行
って乾燥及び選別し、上掛け、コーティング、風乾等の
処理を経て美容食品の錠剤を完成させる。なお、美容食
品は、錠剤のみならず、顆粒剤、細粒剤、散剤、カプセ
ル剤、トローチ剤等の固形製剤、乳剤、シロップ剤、懸
濁剤等の液製剤等にすることもできる。Hyaluronic acid, glucosamine, oligosaccharides,
After preparing vitamin C, excipients, etc., they are weighed to a predetermined amount and mixed by a stirrer, and the mixture is compressed into a predetermined shape by tableting using a tableting machine. After drying and sorting, the product is coated, coated, air-dried, etc. to complete the cosmetic food tablets. The cosmetic food can be not only tablets but also solid preparations such as granules, fine granules, powders, capsules, and troches, and liquid preparations such as emulsions, syrups, and suspensions.
【0032】ここで、美容食品に含まれるヒアルロン
酸、グルコサミン、オリゴ糖、ビタミンCの各成分等の
重量比は、全体の1の重量に対してヒアルロン酸を0.
01〜0.25、好ましくは0.05〜0.20と、全
体の1の重量に対してグルコサミンを0.005〜0.
15、好ましくは0.020〜0.100と、全体の1
の重量に対してオリゴ糖を0.02〜0.35、好まし
くは0.05〜0.30と、全体の1の重量に対してビ
タミンCを0.01〜0.25、好ましくは0.05〜
0.25としている。Here, the weight ratio of each component of hyaluronic acid, glucosamine, oligosaccharide, vitamin C, etc. contained in the beauty food is such that hyaluronic acid is 0.1% to 1 weight of the whole.
Glucosamine is 0.001 to 0.25, preferably 0.01 to 0.25, preferably 0.05 to 0.20.
15, preferably 0.020 to 0.100, and 1
0.02 to 0.35, preferably 0.05 to 0.30, of oligosaccharide based on the weight of vitamin C, and 0.01 to 0.25, preferably 0.1 to 0.2 of vitamin C, based on the total weight of 1. 05-
0.25.
【0033】次に、本実施の美容食品を用いた各試験に
ついて説明するが、本発明はこれら試験に限定されるも
のではない。尚、試験での配合割合は特に断らない限り
重量%で表示される。Next, each test using the beauty food of the present embodiment will be described, but the present invention is not limited to these tests. In addition, the compounding ratio in the test is indicated by weight% unless otherwise specified.
【0034】《試験1》試験1は、ラットを用いたヒア
ルロン酸の消化吸収試験である。 1)試験区と試験方法 ラットを用いたヒアルロン酸(以下HAとする)の消化
吸収試験を次のようにして行った。初体重65g(0.
64N)内外のウィスター系雄ラットを供試動物とし一
群10匹を用い、試験区は表1に示す組成の飼料を用い
た。<< Test 1 >> Test 1 is a digestion and absorption test of hyaluronic acid using rats. 1) Test plot and test method A digestion and absorption test of hyaluronic acid (hereinafter, referred to as HA) using rats was performed as follows. Initial weight 65g (0.
64N) Wistar male rats inside and outside were used as test animals, and 10 rats were used per group. The test group used a feed having the composition shown in Table 1.
【0035】飼料組成(%)Feed composition (%)
【表1】 [Table 1]
【0036】試験区1はセルロース粉末2%を添加した
対照食区と、試験区2はセルロース粉末の代りに鶏冠由
来の分子量約100万の高分子HAを2%添加の高分子
HA2%食区と、試験区3は分子量5〜10万の低分子
HAを2%添加の低分子HA2%区と、試験区4は本発
明品2%区と、試験区5は本発明区と比較するためにヒ
アルロン酸とグルコサミンを含有する食品(以下HAG
とする)2%区とした。ここで、使用した本発明品は1
000g(9.80N)中にヒアルロン酸60g(0.5
9N)、グルコサミン塩酸塩20g(0.20N)、イソ
マルトオリゴ糖100g(0.98N)、ビタミンC12
0g(1.18N)を含有したものである。各群とも一週
間予備飼育をした後、各試験食で飼育した。飼料及び飲
料水は自由に摂取させた。Test plot 1 was a control diet to which 2% of cellulose powder was added, and test plot 2 was a diet 2% of high-molecular-weight HA to which 2% of high molecular weight HA derived from cockscomb was added instead of cellulose powder. Test section 3 is for comparison with low-molecular-weight HA 2% with 2% addition of low-molecular-weight HA having a molecular weight of 50,000 to 100,000, test section 4 is for comparison with the present invention 2% section, and test section 5 is for comparison with the present invention section. Containing hyaluronic acid and glucosamine (hereinafter HAG)
2%. Here, the product of the present invention used was 1
60 g of hyaluronic acid (0.5 g in 9.80 N)
9N), glucosamine hydrochloride 20g (0.20N), isomaltooligosaccharide 100g (0.98N), vitamin C12
It contained 0 g (1.18 N). Each group was preliminarily reared for one week and then reared on each test meal. Food and drinking water were available ad libitum.
【0037】2)消化試験 飼育開始後3週齢目に実施した。結果を表2に示す。数
値は平均値±標準偏差で示している。糞中のHAの定量
は次の様にして行った。(糞中よりの抽出方法)乾燥粉
末糞500mg(4.90×10-3N)を精秤し、クロロ
ホルム:メタノール=2:1の混液で、更にエタノール
で脱脂した。これを蒸留水に懸濁させ更に除蛋白のため
にトリクロロ酢酸を加え冷却した後4℃で遠心分離し上
澄液を透析し、透析内液を試験液とした。(電気泳動
法)上記試験液を畑・木幡の方法(Anal.Biochem.,
45 462(1972) )に準じてセルロースアセ
テート膜による電気泳動法でヒアルロン酸を分析した。
ヒアルロン酸を各々0.10mg/ml、0.25mg/ml、0.
50mg/mlの濃度に溶解し標準液として3μlをスポット
して電気泳動を行い各標準液の濃度をデンシトメターで
測定し標準曲線を作製する。試験液も3μlをスポット
して同様な泳動を行い標準曲線よりヒアルロン酸の濃度
を算出した。2) Digestion test The digestion test was performed at the age of 3 weeks after the start of breeding. Table 2 shows the results. Numerical values are shown as mean ± standard deviation. The quantification of HA in feces was performed as follows. (Extraction method from feces) 500 mg (4.90 × 10 −3 N) of dry powdered feces was precisely weighed, defatted with a mixed solution of chloroform: methanol = 2: 1, and further with ethanol. This was suspended in distilled water, trichloroacetic acid was further added for deproteinization, and the mixture was cooled, centrifuged at 4 ° C., and the supernatant was dialyzed. (Electrophoresis method) The above test solution was subjected to the method of Hata and Kohata (Anal. Biochem.,
45 462 (1972)), and hyaluronic acid was analyzed by an electrophoresis method using a cellulose acetate membrane.
Hyaluronic acid was added at 0.10 mg / ml, 0.25 mg / ml and 0.2 mg, respectively.
After dissolving to a concentration of 50 mg / ml, spotting 3 μl as a standard solution and performing electrophoresis, the concentration of each standard solution is measured by densitometer to prepare a standard curve. The same electrophoresis was performed by spotting 3 μl of the test solution, and the concentration of hyaluronic acid was calculated from the standard curve.
【0038】吸収試験Absorption test
【表2】 飼料摂取量は試験区1はセルロース、試験区2〜5はヒ
アルロン酸としての摂取量を示している。[Table 2] As for the feed intake, the test plot 1 shows the intake as cellulose, and the test plots 2 to 5 show the intake as hyaluronic acid.
【0039】分析一日あたりの飼料摂取量は本発明品食
区、HAG食区、ヒアルロン酸食区、対照区と大差はな
かった。排泄糞量は本発明品食区は対照区よりも低く、
ヒアルロン酸区は対照区よりも明らかに低かった。これ
は対照区のセルロースが消化されなくて排泄されたのに
対しヒアルロン酸は消化されているのでトータル排泄糞
量は少なくなったと考えられる。糞中のヒアルロン酸量
は1.4〜2.5mg/日であった。これより計算すると摂
取されたヒアルロン酸は殆ど何らかの形で消化されてい
ることが明らかである。吸収率ではヒアルロン酸の分子
量による差はなかった。この結果よりヒアルロン酸は分
子量に関係なく消化吸収され食品として利用されること
が明らかとなった。水分量が対照区が多いのは排泄され
たセルロースが水分を抱き込む形になっているものと推
定される。Analysis The daily feed intake was not much different from the diet of the present invention, the HAG diet, the hyaluronic acid diet, and the control plot. Excretion amount of the present invention is lower in the diet group than in the control group,
The hyaluronic acid group was clearly lower than the control group. This is considered to be due to the fact that hyaluronic acid was digested while the cellulose in the control group was not digested and excreted, so that the total excreted feces was reduced. The amount of hyaluronic acid in feces ranged from 1.4 to 2.5 mg / day. Calculations from this show that the ingested hyaluronic acid has been digested almost in some way. There was no difference in absorption rate due to the molecular weight of hyaluronic acid. From this result, it became clear that hyaluronic acid was digested and absorbed regardless of the molecular weight and used as food. It is presumed that the amount of water in the control group is large because the excreted cellulose has a form that embraces water.
【0040】《試験2》試験2は、腸内細菌に及ぼす本
発明品の影響について代表的な腸内細菌であるラクトバ
チルス菌とビフィズス菌に関して検討したものである。
表1の試験区1より試験区4の飼料組成で飼育し飼育開
始より45日目にメンブタール麻酔下、心臓から採血し
た。直ちに内容物を含む盲腸を摘出し氷冷下盲腸内容物
1gを9mlの嫌気性希釈液に混和した。これを10-1希
釈液とし順次10倍希釈を行い10-1〜10-8希釈液を
調整した。盲腸内の細菌フローラーの測定には光岡の方
法に従って行った。ラクトバチルス菌とビフィズス菌の
培養はGAMブイヨン(日水製)を用い、ビフィズス菌の
場合は簡易嫌気培養法としてガスパウチ法で行った。<< Test 2 >> In Test 2, the effect of the product of the present invention on intestinal bacteria was examined for Lactobacillus bacteria and Bifidobacteria, which are typical intestinal bacteria.
The animals were bred with the feed composition of Test Group 1 to Test Group 4 in Table 1 and blood was collected from the heart under membrane anesthesia on day 45 from the start of breeding. Immediately, the cecum containing the contents was removed, and 1 g of the contents of the cecum was mixed with 9 ml of an anaerobic diluent under ice cooling. This was used as a 10 -1 diluent and serially diluted 10-fold to prepare 10 -1 to 10 -8 diluents. The bacterial flora in the cecum was measured according to the method of Mitsuoka. Lactobacillus and bifidobacteria were cultured using GAM bouillon (manufactured by Nissui), and bifidobacteria were cultured by the gas pouch method as a simple anaerobic culture method.
【0041】菌数は盲腸内容物1g当りの常用対数(例
えば8は108を表す)で表し、結果を表3に示す。各
測定値は菌数の平均値±標準偏差で示している。The number of bacteria is represented by a common logarithm (for example, 8 represents 10 8 ) per 1 g of cecal contents. The results are shown in Table 3. Each measured value is shown as the average of the number of bacteria ± standard deviation.
【0042】腸内細菌の変遷Changes in intestinal bacteria
【表3】 [Table 3]
【0043】ラクトバチルス菌の場合は高分子ヒアルロ
ン酸食区では明らかに対照区に比較して10倍以上の増
加であった。低分子ヒアルロン酸食区では有意差は認め
られないが、本発明品食区はどの区よりも多かった。
又、HAG食区も増加は認められず、本発明品食区には
及ばなかった。一方、ビフィズス菌の場合は高分子ヒア
ルロン酸食区では明らかに対照区に比較して70倍位の
増加であり、低分子ヒアルロン酸食区では10倍以上の
増加であった。本発明品食区の増加は顕著であり、低分
子ヒアルロン酸食区では10以上の増加であった。HA
G食区でも増加したが本発明品食区には及ばず、本発明
品食区の増加が最も顕著であった。In the case of Lactobacillus bacteria, the increase was clearly 10 times or more in the high-molecular-weight hyaluronic acid diet as compared with the control. Although no significant difference was observed in the low-molecular-weight hyaluronic acid diet, the present product diet was higher than any of the diets.
In addition, no increase was observed in the HAG diet, and it did not reach the diet of the present invention. On the other hand, in the case of the Bifidobacterium, the increase in the high-molecular-weight hyaluronic acid diet was clearly 70-fold greater than that in the control group, and the increase in the low-molecular-weight hyaluronic acid diet was 10-fold or more. The increase in the diet of the present invention was remarkable, and the increase was 10 or more in the low molecular weight hyaluronic acid diet. HA
The increase was also observed in the G diet, but not as high as that of the diet diet of the present invention.
【0044】《試験3》試験3は、皮膚中のヒアルロン
酸量を測定したものである。皮膚中のヒアルロン酸の抽
出及び定量は木花等の方法(日皮会誌、95,979
(1985))の方法を改良した金丸等の方法(第45回
SCCJ研究会講演要旨集、45)に準じ以下のように行
った。飼育45日後のラット頭部の皮膚直径1.15cm
を摘出し、皮下組織を除去した真皮部を細かく細断し
た。皮膚片に除脂質のためにアセトンを加え、激しく攪
拌した後、遠心分離で皮膚片を沈殿させた(3回)。一
昼夜水流減圧下、アセトンを完全に除去した。これに蒸
留水を加えて10分間煮沸し、内在酵素を不活性にした
後、ガラスホモジナイザーで粉砕後凍結乾燥した。乾燥
物を0.5N-カセイソーダに完全に分散し、4℃で15
時間振とうし可溶化させた。塩酸でpH7.5に調製し、
等量の50mMのトリス塩酸緩衝液(pH7.5)を加え
た。ヒアルロン酸と結合しているタンパク質を分解する
ためにアクチナーゼ(5mg/ml)を加え、50℃で24
時間消化した。前日の半量のアクチナーゼを更に加え、
再び50℃で24時間消化した。除タンパクのために終
濃度が10%になるようにトリクロロ酢酸を加え低温で
静置したのち、4℃で10,000×g、30分間遠心分
離し上澄液を回収した。上澄液の3倍量の氷冷1.3%-
酢酸カリウム・エタノールを加えヒアルロン酸を不溶と
し、10,000×gで15分間遠心分離してヒアルロン
酸を得た。ヒアルロン酸の定量は前述の電気泳動方法で
行った。結果を表4に示す。<< Test 3 >> In Test 3, the amount of hyaluronic acid in the skin was measured. Extraction and quantification of hyaluronic acid in the skin was carried out by the method of Kihana et al.
Kanamaru et al. (45)
The following was conducted in accordance with the abstract of the SCCJ meeting, 45). 45 days after breeding, the skin diameter of the rat head is 1.15 cm.
Was removed, and the dermis portion from which the subcutaneous tissue was removed was finely cut. Acetone was added to the skin pieces to remove lipids, and after vigorous stirring, the skin pieces were precipitated by centrifugation (3 times). Acetone was completely removed under reduced pressure of the water flow all day and night. Distilled water was added to the mixture, and the mixture was boiled for 10 minutes to inactivate the endogenous enzyme, and then pulverized with a glass homogenizer and freeze-dried. The dried product was completely dispersed in 0.5N caustic soda,
Shake for time to solubilize. Adjusted to pH 7.5 with hydrochloric acid,
An equal volume of 50 mM Tris-HCl buffer (pH 7.5) was added. Actinase (5 mg / ml) was added to degrade proteins bound to hyaluronic acid,
Digested for hours. Add half the amount of actinase from the previous day,
Digestion was performed again at 50 ° C. for 24 hours. To remove protein, trichloroacetic acid was added to a final concentration of 10%, the mixture was allowed to stand at low temperature, and then centrifuged at 10,000 xg for 30 minutes at 4 ° C to collect a supernatant. Ice-cooled 1.3% of 3 times the supernatant
Hyaluronic acid was made insoluble by adding potassium acetate / ethanol, and centrifuged at 10,000 × g for 15 minutes to obtain hyaluronic acid. The quantification of hyaluronic acid was performed by the above-mentioned electrophoresis method. Table 4 shows the results.
【0045】皮膚中のヒアルロン酸量(mg/g乾燥重
量)The amount of hyaluronic acid in the skin (mg / g dry weight)
【表4】 [Table 4]
【0046】対照区に比較して本発明品食区の皮膚中の
ヒアルロン酸は増加した。この結果、皮膚の保湿性、弾
力性に効果があることが明らかとなった。The amount of hyaluronic acid in the skin of the diet of the present invention was increased as compared with the control. As a result, it was clarified that there was an effect on the moisture retention and elasticity of the skin.
【0047】《試験4》試験4は、本発明品の人に対す
る臨床的検討を次の様にして行ったものである。 [本試験に使用した食品の調製法]: 1粒中の成分 ヒアルロン酸 30mg(2.94×10-4N) グルコサミン 10mg(0.98×10-4N) イソマルトオリゴ糖 50mg(4.90×10-4N) ビタミンC 60mg(5.88×10-4N) 賦形剤 100mg(9.80×10-4N) 上記の成分を混合し乾燥後パラチノース、ゼラチン等5
00mg(4.90×10-3N)で糖衣した。 [対象人]:日頃慢性的に肌が乾燥して肌荒れに悩んで
いる女性とした。プラセボ群は15名、本発明品群は1
3名であった。 [試験方法]: (1)被験食品:上記の本発明品と、本発明品と外観、
味(無臭)を同一にした擬似食品(プラセボ群)を夫々
一日、9粒、3粒を6週間摂取した。 (2)検査方法: 1.皮膚科的診察・問診:全身所見においては、掻痒、
乾燥、潮紅、びらん、落屑、丘疹、小水泡、腫脹を、ま
た顔面の所見においては化粧かぶれ、乾燥、潮紅、化粧
のりについて各4段階で評価した。また、顔面及び全身
所見の総合的な所見について、全般症状として評価し
た。 2.水分量、油分量、酸性度(pH):水分量は、Courag
e Khazaka Electronic Gmbh社製のCorneometric CM
825を用いて測定した。油分量はCourage Khazaka
Electronic Gmbh社製のSubumeter SM810を用いて測
定した。酸性度はCourage Khazaka Electronic Gmbh
社製のPH900を用いて測定した。測定部位は左眼下1
cm、左上腕内側部(肘上3cm)及び頚背部(頚部の棘状
突起下3cm)とした。なお、測定はできるだけ環境を同
一に保つために測定前には一定条件に設定した部屋(室
温18〜20℃、湿度45〜60%)を用意し、被験者
には30分間以上安静にしてもらった。出来る限り同一
の時間に測定した。測定部位の化粧は原則として検査6
0分前から禁止した。 3.顕微鏡的3次元皮膚表面解析装置による解析:顕微
鏡的3次元皮膚表面解析装置はCourage Khazaka Elec
tronic Gmbh社製の皮膚表面デジタル解析装置(VISIOS
CAN)で皮膚の表面を特殊な紫外線で照射し、その画像
をデジタル処理し評価するものである。 1)SEsm(Skin Smoothness):皮膚の滑らかさの指標
のひとつである。皺の幅と深さと平均から算出する。数
値が低いほど滑らかであることを示す。 2)SEr(Skin roughness):皮膚の粗さを示す指標の
ひとつである。画像全体に占める設定ポイント以上に暗
いポイントの割合を計算し算出した。数値が低いほど滑
らかであり、数値が高いほど粗いことを示す。 3)SEsc(Skin Scaliness):鱗屑(角質の乾燥の度
合い)の指標のひとつである。皮膚剥離した部分が画像
では明るくカウントされることにより、全体に占める設
定した値より明るい部分の占める割合を算出する。数値
が低いほど濁っていて剥離(鱗屑)が少ないことを示
す。 4)SEw(Skin Wrinkle):皮膚の皺の数と幅を示す指
標のひとつである。皮膚の垂直方向、水平方向のきめ、
又は皺の数と幅を示す。この数値が高いほど、皺が多
く、かつ皺が幅広いことを示す。 5)Kurtosis(補正K):肌全体の滑らかさを示す。肌の
色調ポイントのヒストグラフの質を示しており、値が0
に近いほど色調ポイントのヒストグラムが滑らかな曲線
であることを示し、理想の肌を示す。Test 4 Test 4 is a clinical study of the product of the present invention on humans as follows. [Preparation method of food used in this test]: Ingredients in one grain Hyaluronic acid 30 mg (2.94 × 10 −4 N) Glucosamine 10 mg (0.98 × 10 −4 N) Isomaltooligosaccharide 50 mg (4.90) × 10 −4 N) Vitamin C 60 mg (5.88 × 10 −4 N) Excipient 100 mg (9.80 × 10 −4 N) The above components are mixed and dried, and then palatinose, gelatin, etc. 5
It was sugar-coated with 00 mg (4.90 × 10 −3 N). [Subject]: A woman suffering from dry skin and rough skin. Placebo group: 15 people, product group of the present invention: 1
There were three people. [Test method]: (1) Test food: the above-described present product, the present product and appearance,
Simulated foods (placebo group) having the same taste (odorless) were ingested daily for 9 weeks and 3 tablets for 6 weeks. (2) Inspection method: Dermatological examinations and interviews: pruritus,
Dryness, flushing, erosion, desquamation, papules, small blisters, and swelling, and facial findings were evaluated for makeup rash, dryness, flushing, and makeup glue on a four-point scale. In addition, comprehensive findings of facial and systemic findings were evaluated as general symptoms. 2. Water content, oil content, acidity (pH): Water content is Courag
Corneometric CM from e Khazaka Electronic Gmbh
825. Oil content is Courage Khazaka
The measurement was performed using a Subumeter SM810 manufactured by Electronic Gmbh. Acidity is Courage Khazaka Electronic Gmbh
The measurement was carried out using PH900 manufactured by the company. The measurement site is below the left eye 1
cm, left upper arm inner part (3 cm above the elbow) and cervical back (3 cm below the spinous process of the neck). In addition, in order to keep the environment as identical as possible, a room (room temperature 18-20 ° C., humidity 45-60%) set under constant conditions was prepared before the measurement, and the subjects were allowed to rest for 30 minutes or more. . Measurements were taken at the same time as possible. Inspection of makeup at the measurement site is in principle 6
Banned 0 minutes ago. 3. Analysis with a microscopic three-dimensional skin surface analyzer: Courage Khazaka Elec
skin surface digital analyzer (VISIOS manufactured by tronic Gmbh)
CAN) irradiates the surface of the skin with special ultraviolet rays, and digitally processes and evaluates the image. 1) SEsm (Skin Smoothness): One of the indicators of skin smoothness. Calculated from wrinkle width, depth and average. The lower the value, the smoother it is. 2) SEr (Skin roughness): This is one of the indexes indicating skin roughness. The ratio of points darker than the set points in the entire image was calculated and calculated. The lower the numerical value, the smoother the surface. The higher the numerical value, the coarser the surface. 3) SEsc (Skin Scaliness): One of the indicators of scale (the degree of keratin drying). The portion where the skin has peeled off is counted brightly in the image, and the proportion of the portion that is brighter than the set value in the whole is calculated. The lower the value, the more turbid and less exfoliation (scale). 4) SEw (Skin Wrinkle): One of the indexes indicating the number and width of skin wrinkles. Vertical and horizontal texture of the skin,
Alternatively, it indicates the number and width of wrinkles. The higher the value, the more wrinkles and the wider the wrinkles. 5) Kurtosis (correction K): indicates the smoothness of the entire skin. Indicates the quality of the histogram of the skin tone point, with a value of 0
The closer to, the smoother the histogram of the color tone point is, indicating an ideal skin.
【0048】[臨床試験結果] (1)皮膚科的診察結果:皮膚科的診察の結果の摂取前
後の推移を表5に示す。値はいずれも「0(症状な
し)」から「3(重度)」までの4段階評価の個人スコ
アの平均値を便宜的に示している。経過としてスコアが
低くなると改善していることを示している。顔面の症状
においては、本発明品群の「顔の肌の乾燥」の観察項目
で、摂取3週間後と6週間後に有意な改善を認めた。プ
ラセボ群では顔の症状評価において一切有意な改善を認
めなかった。また、全身の所見では本発明品群では「掻
痒」、「乾燥」、「潮紅」で有意な改善が見られた。一
方、プラセボ群では「乾燥」において有意な改善が見ら
れたものの、他の評価項目では有意な改善は見られなか
った。[Clinical Test Results] (1) Dermatological Examination Results: Table 5 shows changes in the results of the dermatological examination before and after ingestion. Each value indicates the average value of the individual scores of the four-level evaluation from “0 (no symptom)” to “3 (severe)” for convenience. The lower the score over time, the better. With respect to the facial symptoms, significant improvement was observed 3 weeks and 6 weeks after ingestion of the observation item of "drying of facial skin" in the product group of the present invention. No significant improvement in facial symptom evaluation was observed in the placebo group. Further, in the whole body findings, significant improvement was observed in "pruritus", "dryness" and "flushing" in the product group of the present invention. On the other hand, the placebo group showed a significant improvement in “dryness”, but no significant improvement was seen in the other evaluation items.
【0049】皮膚科的診察結果Dermatological examination results
【表5】 値は各被験者の平均値を示す(統計検定はnon-parametr
icを採用)[Table 5] The value indicates the average value of each subject (statistical test is non-parametr
ic)
【0050】(2)水分量、油分量、酸性度の結果:表
6に水分量、油分量、酸性度の摂取前後の推移を示す。
水分量においてプラセボ群の左眼下部位で6週間後に有
意な減少が見られたのに対し、本発明品群では対照的に
6週間後に水分量に有意な増加が観察された。油分量は
左眼下部以外は殆どの被験者で0であったため、2回目
の検査より左上腕及び頚背部の測定を除外した。結果と
して本発明品群では油分量の有意な減少が観察された。(2) Results of water content, oil content and acidity: Table 6 shows changes in water content, oil content and acidity before and after intake.
In the placebo group, a significant decrease in the water content was observed at 6 weeks after the left eye in the placebo group, whereas in the group of the present invention, in contrast, a significant increase in the water content was observed after 6 weeks. Since the oil content was 0 in most subjects except for the lower part of the left eye, the measurement of the left upper arm and the back of the neck was excluded from the second examination. As a result, a significant decrease in the oil content was observed in the product group of the present invention.
【0051】皮膚の水分、pH、油分の測定結果Measurement results of moisture, pH and oil content of skin
【表6】 値は各被験者の平均値を示す(統計検定はnon-parametr
icを採用)[Table 6] The value indicates the average value of each subject (statistical test is non-parametr
ic)
【0052】(3)顕微鏡的3次元皮膚表面解析装置
(VISIOSCAN)による解析結果:VISIOSCANにより画像解
析された各パラメータ値の推移を表7に示す。SEsm値に
おいては、頚背部位で本発明品群は有意な改善を示し、
肌の滑らかさが回復していることが示された。一方プラ
セボ群は改善を認めなかった。また、SEscにおいても本
発明品群は頚背部において有意な回復がみられたが、プ
ラセボ群においては有意な回復は一切認めなかった。
他、Kurtosisでプラセボ群の左上部位で悪化傾向を認め
たの対し、本発明品群では改善を認め、対照的な結果を
得た。尚、SEr及びSEwにおいては両群とも顕著な変化は
認めなかった。(3) Analysis result by microscopic three-dimensional skin surface analyzer (VISIOSCAN): Table 7 shows the transition of each parameter value image-analyzed by VISIOSCAN. In the SEsm value, the product group of the present invention shows a significant improvement in the back of the neck,
It was shown that the smoothness of the skin was restored. On the other hand, no improvement was observed in the placebo group. In the case of SEsc, significant recovery was observed in the present invention group in the back of the neck, but no significant recovery was observed in the placebo group.
In addition, Kurtosis showed a worsening tendency in the upper left region of the placebo group, while the Kurtosis group showed an improvement in the case of the present invention group, and obtained a contrasting result. There was no significant change in SEr and SEw in both groups.
【0053】VISIOSCANによる測定パラメータ値Parameter values measured by VISIOSCAN
【表7】 値は各被験者の平均値を示す(統計検定はnon-parametr
icを採用)[Table 7] The value indicates the average value of each subject (statistical test is non-parametr
ic)
【0054】《試験5》試験5は、本発明品をパネルリ
ストに用いた際における肌の状態と便通の美容作用の有
無を示すものである。表8に示す配合割合の成分を混和
後常法により顆粒化した本発明の食品組成物を調整し
た。各試験区の食品組成物を各区40人の女性パネラー
に60日間、毎日4g(3.92×10-4N)ずつ摂取し
てもらい肌の状態と便通の変化を観察した。60日後の
結果を表9に示す。Test 5 Test 5 shows the condition of the skin when the product of the present invention is used in the panel list and the presence or absence of a cosmetic effect of bowel movement. After mixing the components at the mixing ratios shown in Table 8, the food composition of the present invention was granulated by a conventional method. Forty days each of the female compositions of each test group were ingested 4 g (3.92 × 10 −4 N) for 60 days by female panelists for 60 days, and changes in skin condition and bowel movement were observed. The results after 60 days are shown in Table 9.
【0055】食品配合割合(%)Food mix ratio (%)
【表8】 [Table 8]
【0056】パネルテスト結果(人/40人)Panel test result (person / 40)
【表9】 [Table 9]
【0057】HAG食区でも肌の改善、便秘の改善はみ
られたが、本発明品区の改善の効果は著しく、本発明品
の各配合素材の配合が美容食品として優れていることを
示している。なお、本発明品の美容食品の摂取量は0.
02〜20g/kg・日が望ましい。Although the improvement of skin and improvement of constipation were observed in the HAG diet, the effect of the improvement of the product of the present invention was remarkable, indicating that the composition of each compound material of the product of the present invention was excellent as a beauty food. ing. In addition, the intake of the beauty food of the product of the present invention is 0.5.
It is preferably from 02 to 20 g / kg · day.
【0058】試験1〜試験5に示すように、本発明の美
容食品は、ヒアルロン酸が腸内細菌により利用されて腸
管から吸収され、血清中の抗高脂血症、腸内の有益なラ
クトバチルス菌を増加させることを初めて明らかにし、
美容作用をパネリストの肌の触感テストや便秘テストの
みならず科学的に立証した。又、分子量は今まで利用性
から考えて50万以下の低分子のもが適当とされてきた
が、本発明により100万前後のものでも十分にヒアル
ロン酸は腸内で利用されることが判明し、むしろ高分子
のものが低分子のものより腸内のラクトバチルス菌、ビ
フィズス菌の増加に効果を発揮した。As shown in Tests 1 to 5, the cosmetic food of the present invention is characterized in that hyaluronic acid is utilized by intestinal bacteria and is absorbed from the intestinal tract, anti-hyperlipidemia in serum, beneficial lactone in intestine For the first time, it was revealed that Bacillus bacteria increased,
The beauty effect was scientifically verified as well as a panelist's skin tactile test and constipation test. Although the low molecular weight of 500,000 or less has been considered appropriate from the viewpoint of availability, it has been found that hyaluronic acid can be sufficiently used in the intestine even with a molecular weight of about 1,000,000. Rather, the high molecular weight compounds were more effective at increasing the number of lactobacilli and bifidobacteria in the intestine than the low molecular weight ones.
【0059】従って、本発明の美容食品を経口摂取した
際には、ヒアルロン酸、グルコサミン、オリゴ糖、ビタ
ミンCの成分の相乗効果により、各成分の個々の効果を
足したものよりも、皮膚中のヒアルロン酸やコラーゲン
の産生を高める等の優れた美容作用を生じることができ
る。Therefore, when the cosmetic food of the present invention is orally ingested, the synergistic effect of the components of hyaluronic acid, glucosamine, oligosaccharides and vitamin C makes it possible for the skin effect to be higher than the sum of the individual effects of the components. An excellent cosmetic action such as enhancing production of hyaluronic acid and collagen can be produced.
【0060】本発明の美容食品は、全体の1の重量に対
して、ヒアルロン酸の重量比を0.01〜0.25、グ
ルコサミンの重量比を0.005〜0.15、オリゴ糖
の重量比を0.02〜0.35、ビタミンCの重量比を
0.01〜0.25にすると、確実に美容作用を得るこ
とができる。ここで、全体の1の重量に対して各成分の
重量比を上記範囲より大きくすると、美容作用が低減す
る傾向にあると共に製造コストが増加するという問題が
あり、全体の1の重量に対して各成分の重量比を上記範
囲未満にすると、美容作用が著しく低減する。ちなみに
全体の1の重量に対してヒアルロン酸の重量比を0.0
5〜0.20、グルコサミンの重量比を0.02〜0.
10、オリゴ糖の重量比を0.05〜0.30、ビタミ
ンCの重量比を0.05〜0.25にした場合には、特
に最適な美容作用を得ることができる。The beauty food of the present invention has a weight ratio of hyaluronic acid of 0.01 to 0.25, a weight ratio of glucosamine of 0.005 to 0.15, and a weight of oligosaccharide, relative to the total weight of 1. When the ratio is set to 0.02 to 0.35 and the weight ratio of vitamin C is set to 0.01 to 0.25, a cosmetic effect can be surely obtained. Here, when the weight ratio of each component to the total weight of 1 is larger than the above range, there is a problem that the cosmetic effect tends to decrease and the manufacturing cost increases. When the weight ratio of each component is less than the above range, the cosmetic effect is significantly reduced. Incidentally, the weight ratio of hyaluronic acid to 0.01
5 to 0.20, the weight ratio of glucosamine is 0.02 to 0.
10. When the weight ratio of the oligosaccharide is set to 0.05 to 0.30 and the weight ratio of vitamin C is set to 0.05 to 0.25, a particularly optimal cosmetic effect can be obtained.
【0061】ヒアルロン酸の分子量を60万から200
万にすると、50万以下の低分子量のものに比べて腸内
のラクトバチルス菌、ビフィズス菌を増加させるので整
腸作用を増進し、美容作用を一層高めることができる。The molecular weight of hyaluronic acid is increased from 600,000 to 200
When the amount is 10,000, lactobacilli and bifidobacteria in the intestine are increased as compared with those having a low molecular weight of 500,000 or less, so that the intestinal regulation action is enhanced and the cosmetic action can be further enhanced.
【0062】ヒアルロン酸を鶏冠より抽出し若しくは微
生物の発酵により製造させると、従来、ヒアルロン酸を
50万以下の分子量にするために必要であった高圧、高
温、酵素の処理を不要にし、製造コストを低減すること
ができる。When hyaluronic acid is extracted from a cockscomb or produced by fermentation of microorganisms, high-pressure, high-temperature, and enzyme treatments conventionally required to reduce the molecular weight of hyaluronic acid to 500,000 or less are unnecessary, and the production cost is reduced. Can be reduced.
【0063】グルコサミンを、2-アミノ-2-デオキシ-
D-グルコース又は2-アミノ-2-デオキシ-D-グルコース
の塩で構成し、オリゴ糖を、マルトオリゴ糖、ガラクト
オリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖、ゲ
ンチオオリゴ糖、ラクトスクロース、トレハロースのう
ち少なくとも1種以上で構成すると、美容作用を高める
と共に製造コストを一層低減することができる。Glucosamine is converted to 2-amino-2-deoxy-
D-glucose or 2-amino-2-deoxy-D-glucose salt, wherein the oligosaccharide is at least one of maltooligosaccharide, galactooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, gentiooligosaccharide, lactosucrose and trehalose With the above configuration, the cosmetic effect can be enhanced and the manufacturing cost can be further reduced.
【0064】なお、本発明の美容食品は、上述の形態例
のみに限定されるものではなく、種々の機能材を加えて
もよいこと、その他、本発明の要旨を逸脱しない範囲内
において種々変更を加え得ることは勿論である。The beauty food of the present invention is not limited to the above-described embodiment, and various functional materials may be added, and various modifications may be made without departing from the gist of the present invention. Can of course be added.
【0065】[0065]
【発明の効果】本発明の美容食品によれば、下記の如き
種々の優れた効果を奏し得る。According to the beauty food of the present invention, various excellent effects as described below can be obtained.
【0066】(I)本発明の美容食品を経口摂取した際
には、ヒアルロン酸、グルコサミン、オリゴ糖、ビタミ
ンCの成分の相乗効果により皮膚中のヒアルロン酸やコ
ラーゲンの産生を高める等の優れた美容作用を生じるこ
とができる。(I) When the cosmetic food of the present invention is orally ingested, it has excellent synergistic effects of components of hyaluronic acid, glucosamine, oligosaccharides and vitamin C, thereby enhancing the production of hyaluronic acid and collagen in the skin. Can produce cosmetic effects.
【0067】(II)ヒアルロン酸の分子量を60万か
ら200万にすると、50万以下の低分子量のものに比
べて腸内のラクトバチルス菌、ビフィズス菌を増加させ
るので整腸作用を増進し、美容作用を一層高めることが
できる。(II) When the molecular weight of hyaluronic acid is from 600,000 to 2,000,000, the number of lactobacilli and bifidobacteria in the intestine is increased as compared with those having a low molecular weight of 500,000 or less, so that the intestinal action is enhanced. Beauty action can be further enhanced.
【0068】(III)ヒアルロン酸を鶏冠より抽出し
若しくは微生物の発酵により製造させると、従来、ヒア
ルロン酸を50万以下の分子量にするために必要であっ
た高圧、高温、酵素の処理を不要にし、製造コストを低
減することができる。(III) When hyaluronic acid is extracted from a cockscomb or produced by fermentation of microorganisms, high-pressure, high-temperature, and enzyme treatments conventionally required to reduce the molecular weight of hyaluronic acid to 500,000 or less become unnecessary. In addition, manufacturing costs can be reduced.
【0069】(IV)グルコサミンを、2-アミノ-2-
デオキシ-D-グルコース又は2-アミノ-2-デオキシ-D-
グルコースの塩で構成し、オリゴ糖を、マルトオリゴ
糖、ガラクトオリゴ糖、フラクトオリゴ糖、イソマルト
オリゴ糖、ゲンチオオリゴ糖、ラクトスクロース、トレ
ハロースのうち少なくとも1種以上で構成すると、美容
作用を高めると共に製造コストを一層低減することがで
きる。(IV) Glucosamine is converted to 2-amino-2-
Deoxy-D-glucose or 2-amino-2-deoxy-D-
When the oligosaccharide is composed of at least one of maltooligosaccharide, galactooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, gentiooligosaccharide, lactosucrose, and trehalose, the cosmetic effect is enhanced and the production cost is further increased. Can be reduced.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 31/702 A61K 31/702 31/715 31/715 31/726 31/726 31/728 31/728 35/12 35/12 A61P 17/00 A61P 17/00 43/00 107 43/00 107 (72)発明者 山形 知広 熊本県鹿本郡植木町岩野45番地 リバテー プ製薬株式会社内 Fターム(参考) 4B018 LE01 MD16 MD25 MD33 MD41 ME14 MF01 MF10 4C086 AA01 AA02 BA18 EA01 EA02 EA20 EA22 EA25 MA03 MA04 MA52 NA05 NA10 ZA89 ZB22 4C087 AA01 AA02 AA03 BB33 MA52 NA05 NA10 ZA89 ZB22 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme court ゛ (Reference) A61K 31/702 A61K 31/702 31/715 31/715 31/726 31/726 31/728 31/728 35 / 12 35/12 A61P 17/00 A61P 17/00 43/00 107 43/00 107 (72) Inventor Tomohiro Yamagata 45 Iwano, Ueki-cho, Kamoto-gun, Kumamoto F-term (reference) 4B018 LE01 MD16 MD25 MD33 MD41 ME14 MF01 MF10 4C086 AA01 AA02 BA18 EA01 EA02 EA20 EA22 EA25 MA03 MA04 MA52 NA05 NA10 ZA89 ZB22 4C087 AA01 AA02 AA03 BB33 MA52 NA05 NA10 ZA89 ZB22
Claims (7)
及びビタミンCを含むことを特徴とする美容食品。1. A beauty food comprising hyaluronic acid, glucosamine, oligosaccharides and vitamin C.
の重量比を0.01〜0.25、グルコサミンの重量比
を0.005〜0.15、オリゴ糖の重量比を0.02
〜0.35、ビタミンCの重量比を0.01〜0.25
にした請求項1に記載の美容食品。2. The weight ratio of hyaluronic acid is 0.01 to 0.25, the weight ratio of glucosamine is 0.005 to 0.15, and the weight ratio of oligosaccharide is 0.02 to 1 weight of the whole.
0.35, the weight ratio of vitamin C is 0.01-0.25
The beauty food according to claim 1, wherein
0万にした請求項1又は2記載の美容食品。3. The molecular weight of hyaluronic acid is from 600,000 to 20
3. The beauty food according to claim 1 or 2, wherein the amount is set at 100,000.
からなる請求項1、2又は3記載の美容食品。4. The beauty food according to claim 1, wherein the hyaluronic acid is extracted from a cockscomb.
emicus、Streptococcus equisimilisの少なくとも一方
の微生物の発酵により製造されたものからなる請求項
1、2又は3記載の美容食品。5. The method according to claim 5, wherein the hyaluronic acid is Streptococcus zoopid.
The cosmetic food according to claim 1, 2 or 3, which is produced by fermentation of at least one of emicus and Streptococcus equisimilis microorganisms.
製造される2-アミノ-2-デオキシ-D-グルコース、又は
2-アミノ-2-デオキシ-D-グルコースの塩の少なくとも
一方からなる請求項1、2又は3記載の美容食品。6. The glucosamine comprises at least one of 2-amino-2-deoxy-D-glucose produced by hydrolyzing chitin, and a salt of 2-amino-2-deoxy-D-glucose. The beauty food according to 1, 2, or 3.
オリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖、ゲ
ンチオオリゴ糖、ラクトスクロース、トレハロースのう
ち少なくとも1種以上からなる請求項1、2又は3記載
の美容食品。7. The cosmetic food according to claim 1, wherein the oligosaccharide comprises at least one of maltooligosaccharide, galactooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, gentiooligosaccharide, lactosucrose, and trehalose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001024457A JP3510861B2 (en) | 2001-01-31 | 2001-01-31 | Beauty food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001024457A JP3510861B2 (en) | 2001-01-31 | 2001-01-31 | Beauty food |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002223726A true JP2002223726A (en) | 2002-08-13 |
JP3510861B2 JP3510861B2 (en) | 2004-03-29 |
Family
ID=18889596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001024457A Expired - Fee Related JP3510861B2 (en) | 2001-01-31 | 2001-01-31 | Beauty food |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3510861B2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004321095A (en) * | 2003-04-25 | 2004-11-18 | Q P Corp | Food or beverage composition |
JP2005080532A (en) * | 2003-09-05 | 2005-03-31 | Pola Chem Ind Inc | Food composition |
JP2006036644A (en) * | 2004-07-22 | 2006-02-09 | Yaizu Suisankagaku Industry Co Ltd | Manufacturing method of glucosamine granule, glucosamine granule and glucosamine tablet |
WO2006054710A1 (en) * | 2004-11-22 | 2006-05-26 | Sunstar Inc. | Agent for ameliorating the maximum passage time through digestive tract, agent for ameliorating passage time through digestive tract and preventive for colon cancer |
JP2007063177A (en) * | 2005-08-31 | 2007-03-15 | Hayashibara Biochem Lab Inc | Composition for oral intake for beautiful skin |
JP2007519620A (en) * | 2003-12-05 | 2007-07-19 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Antidiarrheal composition containing glutamine |
EP2570118A1 (en) * | 2011-09-16 | 2013-03-20 | China Medical University | Combinations of hyaluronic acid and a vitamin for inhibiting inflammation |
FR3012329A1 (en) * | 2013-10-29 | 2015-05-01 | Dermaconcept Jmc | ASSOCIATION VITAMIN C AND HYALURONIC ACID FOR THE TREATMENT OF THE EFFECTS OF SKIN AGING. |
JP2017014164A (en) * | 2015-07-02 | 2017-01-19 | 株式会社東洋新薬 | Joint function improvement agent |
KR20170042707A (en) | 2014-08-20 | 2017-04-19 | 가부시기가이샤하야시바라 | Oral beauty care agent |
JP2019182768A (en) * | 2018-04-06 | 2019-10-24 | 株式会社らいむ | Method for producing protease decomposition composition, method for producing fibroblast proliferation promoter, and method for producing collagen production promoter |
CN115192602A (en) * | 2021-04-14 | 2022-10-18 | 山东华熙海御生物医药有限公司 | Composite prebiotics and application thereof in regulating intestinal function |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000139408A (en) | 1998-11-05 | 2000-05-23 | Yaizu Suisankagaku Industry Co Ltd | Glucosamine-including food |
JP3382871B2 (en) | 1999-02-26 | 2003-03-04 | 株式会社東洋新薬 | healthy food |
-
2001
- 2001-01-31 JP JP2001024457A patent/JP3510861B2/en not_active Expired - Fee Related
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004321095A (en) * | 2003-04-25 | 2004-11-18 | Q P Corp | Food or beverage composition |
JP2005080532A (en) * | 2003-09-05 | 2005-03-31 | Pola Chem Ind Inc | Food composition |
JP2007519620A (en) * | 2003-12-05 | 2007-07-19 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Antidiarrheal composition containing glutamine |
JP2006036644A (en) * | 2004-07-22 | 2006-02-09 | Yaizu Suisankagaku Industry Co Ltd | Manufacturing method of glucosamine granule, glucosamine granule and glucosamine tablet |
WO2006054710A1 (en) * | 2004-11-22 | 2006-05-26 | Sunstar Inc. | Agent for ameliorating the maximum passage time through digestive tract, agent for ameliorating passage time through digestive tract and preventive for colon cancer |
JP2007063177A (en) * | 2005-08-31 | 2007-03-15 | Hayashibara Biochem Lab Inc | Composition for oral intake for beautiful skin |
EP2570118A1 (en) * | 2011-09-16 | 2013-03-20 | China Medical University | Combinations of hyaluronic acid and a vitamin for inhibiting inflammation |
US8835405B2 (en) | 2011-09-16 | 2014-09-16 | China Medical University | Inhibiting arthritis via injection of synergistic combination of hyaluronic acid and vitamin C and/or vitamin E |
FR3012329A1 (en) * | 2013-10-29 | 2015-05-01 | Dermaconcept Jmc | ASSOCIATION VITAMIN C AND HYALURONIC ACID FOR THE TREATMENT OF THE EFFECTS OF SKIN AGING. |
EP2868313B1 (en) * | 2013-10-29 | 2019-06-19 | Dermaconcept JMC | Combination of vitamin C and hyaluronic acid for the treatment of skin ageing effects |
KR20170042707A (en) | 2014-08-20 | 2017-04-19 | 가부시기가이샤하야시바라 | Oral beauty care agent |
JP2017014164A (en) * | 2015-07-02 | 2017-01-19 | 株式会社東洋新薬 | Joint function improvement agent |
JP2019182768A (en) * | 2018-04-06 | 2019-10-24 | 株式会社らいむ | Method for producing protease decomposition composition, method for producing fibroblast proliferation promoter, and method for producing collagen production promoter |
US11179414B2 (en) | 2018-04-06 | 2021-11-23 | Laimu Corporation | Method for producing protease degradation composition |
CN115192602A (en) * | 2021-04-14 | 2022-10-18 | 山东华熙海御生物医药有限公司 | Composite prebiotics and application thereof in regulating intestinal function |
CN115192602B (en) * | 2021-04-14 | 2024-02-02 | 华熙生物科技股份有限公司 | Composite prebiotics and application thereof in regulating intestinal functions |
Also Published As
Publication number | Publication date |
---|---|
JP3510861B2 (en) | 2004-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5894341B2 (en) | Composition comprising collagen peptide, elastin peptide and proteoglycan | |
KR100592690B1 (en) | Skin moisturizer and beauty health food | |
KR101342192B1 (en) | Collagen Production Enhancers and Their Uses | |
JP5653759B2 (en) | Skin aging inhibitory peptide | |
CN113679046B (en) | Composition for promoting interaction of hyaluronic acid and collagen and application thereof | |
CN103415281A (en) | Skin beautifying agent | |
JP3510861B2 (en) | Beauty food | |
JP2000201649A (en) | Dermal metabolism accelerator and functional food | |
JP2002223727A (en) | Functional food | |
JP4097335B2 (en) | Food additive | |
JP4227657B2 (en) | Food additive for skin care | |
JP5635221B2 (en) | Fermented milk for skin improvement and / or treatment and method for producing the same | |
EP3677248A1 (en) | Anti-aging agent for skin and anti-aging-related gene expression regulator | |
US6566346B2 (en) | Oral skin improving agent, skin improving method, and food composition for improving skin | |
JP5722282B2 (en) | Skin improving agent and skin improving method | |
JP2006143671A (en) | Oral skin aging-preventing/improving agent | |
WO2016129174A1 (en) | Hyaluronic acid production promoter | |
Chon et al. | Physiochemical and organoleptic properties of kefir containing different concentrations of hyaluronic acid: A preliminary study | |
CN116098201A (en) | Use of nutritional compositions for improving bone density and bone metabolism | |
JP2000050842A (en) | Food composition | |
JP6348308B2 (en) | Photoaging preventive or ameliorating agent | |
TWI576117B (en) | Hyaluronic acid production promoter | |
TWI602581B (en) | Hyaluronic acid production promoter | |
JP2002080340A (en) | Cosmetological composition | |
CN114304624A (en) | Beverage containing eggshell membrane powder and hydrolyzed eggshell membrane component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20031226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3510861 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090109 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090109 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100109 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100109 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110109 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120109 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130109 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130109 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140109 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |